Market Research Logo

FirstWord

FirstWord belongs to a business group that forms one of the world's largest healthcare knowledge networks. Drawing from these knowledge assets, FirstWord reports deliver insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date, actionable intelligence - reports that deliver vital intelligence to give a competitive edge.
...Show More ...Show Less

451 Reports from FirstWord

   
  • Biosimilars: US Payer Perspectives (2018)

    ... as a solution to stem the tide of soaring drug spending, in the cold light of day, the US biosimilars market has failed to meet expectations. Payers are frustrated. Can the cycle of endless litigation ... Read More

  • Benchmarking Pharma’s MSL Capabilities

    ... new world. The pharma companies getting the best results from their MSLs have been busy: widening their remit, embracing technology, and fine-tuning structure and focus. What does a forward-thinking MSL team now look like? In ... Read More

  • Benchmarking Key Account Management Capabilities

    ... attributes and operational environment that will deliver optimum performance? What number of brands should a team manage? How much time should they be spending with their key accounts? What level of experience do, on average, ... Read More

  • Head and Neck Squamous Cell Carcinoma: KOL Insight [2018]

    ... recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and expectations are high that further approvals will continue to improve treatment outcomes. Could locoregional disease become the next frontier in the battle of the immune checkpoint ... Read More

  • Rheumatoid Arthritis: KOL Insight [2018]

    ... however, Eli Lilly/Incyte’s Olumiant (baricitinib) has managed to get first-to-market advantage in Europe. KOL’s weigh in on how Olumiant is faring in the EU, how its availability is impacting Xeljanz, as well as its chances ... Read More

  • Market Access Impact: HIV (US) 2018

    ... HIV prescriptions, the top brand has a significant lead over all other brands. Find out what’s driving its share gains, and what your brand can do to level the playing field in Market Access Impact: ... Read More

  • KAM Metrics: Driving efficiency and measuring success

    ... teams operate: the challenge now is to use metrics that reflect the diversity of these sophisticated relationships and drive them forwards. But what works for one contact or KAM may not be appropriate for the ... Read More

  • Multiple Myeloma: Update Bulletin #3 [March 2018]

    ... bluebird bio’s presentation of updated findings from a Phase I trial of their anti-BCMA CAR-T cell therapy bb2121 at ASH 2017;Genmab/Janssen Biotech’s publication of preliminary data from the Phase II CENTAURUS trial, evaluating the safety ... Read More

  • Renal Cell Carcinoma: Update Bulletin #3 [March 2018]

    ... Phase III IMmotion151 trial of atezolizumab (Tecentriq) in combination with Avastin (bevacizumab) in meeting its co-primary endpoint of investigator-assessed progression-free survival (PFS); AVEO Oncology and EUSA Pharma presenting positive preliminary findings from the Phase II ... Read More

  • Type 2 Diabetes Mellitus: Update Bulletin #2 [March 2018]

    ... recent events in the type 2 diabetes mellitus (T2DM) market, including; the European Commission’s approval of Novo Nordisk’s Ozempic (semaglutide), a once-weekly GLP-1 receptor agonist, for T2DM; The US FDA approval of Merck & Co’s ... Read More

  • Ulcerative Colitis: Update Bulletin #2 [March 2018]

    ... II trial of Otezla (apremilast) in patients with UC; Protalix BioTherapeutics announcing final dosing of the last patient in a Phase II trial evaluating OPRX 106, an oral anti-TNF, in patients with UC; and Pfizer ... Read More

  • Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018

    ... The 150 medical oncologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put your team ahead of the competition? Discover all the ... Read More

  • Medical Affairs Reputations: Renal Cell Carcinoma (US) 2018

    ... rival. The 100 medical oncologists we polled say that each of those teams needs improvement in at least one specific area, but are those targeted improvements enough to put your team ahead of the competition? ... Read More

  • Market Access Impact: HIV (EU5) 2018

    ... HIV prescriptions, no single brand has a significant lead over other brands. Market share for all players is up for grabs! Find out what’s driving share gains, and what your brand can do to level ... Read More

  • Atopic Dermatitis: Update Bulletin #2 [March 2018]

    ... of initiation of the global Phase III JADE development program for the Janus Kinase 1 (JAK1) inhibitor, PF 04965842, in patients as young as 12 with moderate to severe AD; AbbVie’s presentation of new positive ... Read More

  • Colorectal Cancer: Update Bulletin #2 [March 2018]

    ... MabVax Therapeutics’ human antibody-based radioimmunotherapy product, MVT-1075; views on the new clinical data presented at the ASCO 2018 Gastrointestinal Cancers Symposium for Taiho Oncology’s Lonsurf (trifluridine and tipiracil); views on new data announced from the ... Read More

  • NPS+ Hepatitis C Virus (HCV) Infection US [2018]

    ... some of these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to ... Read More

  • NPS+ Renal Cell Carcinoma (EU5) 2018

    ... levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ RCC (EU5) gives a ... Read More

  • NPS+ Hepatitis C Virus (HCV)Infection (EU5) [2018]

    ... some of these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to ... Read More

  • Medical Affairs Reputations: Non-Small Cell Lung Carcinoma (EU5) 2018

    ... with at least one rival. The 150 medical oncologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put your team ahead of ... Read More

  • Medical Affairs Reputations: Psoriasis (EU5) 2018

    ... with at least one rival. The 150 dermatologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put your team ahead of the ... Read More

  • Biosimilars: EU Payer Perspectives

    ... $232 billion global biologics market is now seriously under threat. New biosimilar entrants have been taking on the European biologic brands for the last decade. The difference is: now they're winning. Are you keeping up ... Read More

  • Market Access Impact: Melanoma (US) 2018

    ... has a significant lead over all other brands. Find out what’s driving its share gains, and what your brand can do to level the playing field in Market Access Impact: Melanoma (US) [2018]. Based on ... Read More

  • NPS+ Renal Cell Carcinoma (US) 2018

    ... levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ RCC (US) gives a ... Read More

  • NPS+ HIV (US) 2018

    ... achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ HIV (US) ... Read More

< prev 1 3 4 5 6 7 8 9 10

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook